U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT06985758) titled 'Pharmacokinetic Study of Rezafungin in Patients With Suspected Intra-Abdominal Candidiasis' on April 24.
Brief Summary: Intra-abdominal candidiasis is the most frequent candidiasis infection after candidemia. The studies that have positioned echinocandins as the first therapeutic option in candidiasis have been carried out mainly in patients with candidemia. Peritoneal concentrations of caspofungin, micafungin and anidulafungin are clearly above the MICs of most Candida spp but are below the threshold for selection of resistant mutants, which has been argued by some researchers as a risk for the control of intra-abdominal infections ...